CRISPR Cholesterol Breakthrough – One Injection, 50% Reduction
Audio Overview
CRISPR Cholesterol Breakthrough – One Injection, 50% Reduction
View Transcript
That possibility moved significantly closer to reality with results from a first-in-human clinical trial published in the New England Journal of Medicine in November 2025.
Researchers at Cleveland Clinic tested an experimental CRISPR gene-editing therapy called CTX310 in fifteen adults with uncontrolled high cholesterol and triglycerides—people whose lipid levels remained dangerously elevated despite taking conventional medications.
The results were striking. A single intravenous infusion of CTX310 reduced LDL cholesterol—the “bad” cholesterol that clogs arteries—by approximately 50 percent. Triglycerides dropped by about 55 percent. And these reductions weren’t temporary; they were sustained for at least 60 days of follow-up, with longer monitoring ongoing.
The therapy works by targeting a gene called ANGPTL3 in the liver. This gene produces a protein that raises both cholesterol and triglyceride levels. By using CRISPR to disable the gene, the treatment essentially reprograms the liver to produce lower levels of these harmful lipids—permanently.
The trial demonstrated favorable safety. No serious adverse events were attributed to the treatment. A few patients experienced minor reactions like back pain or nausea that resolved quickly.
Lead researcher Dr. Luke Laffin called this approach potentially “game-changing” because it addresses one of medicine’s most persistent problems: patients not taking their medications. Half of people prescribed cholesterol drugs stop taking them within a year. A one-time treatment eliminates that issue entirely.
This is still early-stage research—only fifteen patients, with longer follow-up needed to confirm durability and long-term safety. But the proof of concept is powerful: CRISPR gene editing can safely and substantially reduce cardiovascular risk factors with a single treatment.
The Adherence Problem
Cardiovascular disease remains the leading cause of death worldwide, and elevated cholesterol is one of its primary drivers. We have effective medications—statins and newer drugs can dramatically reduce cholesterol levels and cut the risk of heart attacks and strokes.
There’s just one problem: people don’t take them.
Studies consistently show that roughly half of patients prescribed cholesterol-lowering medications stop taking them within a year. Some experience side effects. Some don’t feel any different and question whether the pills are helping. Some simply forget or find daily medication inconvenient. Whatever the reason, the result is the same: elevated cholesterol and elevated cardiovascular risk.
“Treatment adherence is a major issue,” Dr. Steven Nissen, Chief Academic Officer of Cleveland Clinic’s Heart, Vascular & Thoracic Institute and senior author of a groundbreaking new study, observed. “Half of patients… stop taking their medications within a year.”
What if the medication could be made unnecessary—replaced by a single treatment that permanently reprograms the body to produce less cholesterol? That’s precisely what researchers have now demonstrated is possible.
A First-in-Human Trial
Results published in the New England Journal of Medicine in November 2025 document the first clinical trial of CRISPR gene-editing technology for treating high cholesterol. The Phase 1 study, conducted by Cleveland Clinic researchers at six sites across Australia, New Zealand, and the United Kingdom, enrolled fifteen adults with a specific problem: uncontrolled high triglycerides and LDL cholesterol that remained elevated despite conventional medications.
These weren’t typical patients who might respond to better adherence or dose adjustments. They represented the cases where existing approaches had failed.
Each patient received a single intravenous infusion of an experimental therapy called CTX310, developed by CRISPR Therapeutics. The treatment was administered at varying doses—from 0.1 to 0.8 milligrams per kilogram of body weight—to assess both safety and efficacy across a dose range.
The Results
The lipid reductions were substantial.
At the highest dose tested, LDL cholesterol—the primary driver of arterial plaque formation—dropped by approximately 50 percent. Triglycerides, another cardiovascular risk factor associated with heart disease and stroke, fell by roughly 55 percent.
These weren’t gradual changes that emerged over months. Substantial reductions appeared within two weeks of treatment. And crucially, they persisted throughout the minimum 60-day follow-up period, with no signs of wearing off.
Dr. Luke Laffin, a Cleveland Clinic cardiologist and the study’s lead author, noted that this approach could “change the way we treat lipid disorders” by offering a durable one-time intervention rather than lifetime daily medication.
How CRISPR Targeting Works
The therapy targets a gene called ANGPTL3 (angiopoietin-like 3), which produces a protein that regulates lipid metabolism in the liver. When ANGPTL3 is active, it inhibits enzymes that would otherwise clear cholesterol and triglycerides from the bloodstream. The result is higher circulating lipid levels.
CTX310 uses CRISPR-Cas9 technology to make precise cuts in the ANGPTL3 gene within liver cells, effectively disabling it. Once disabled, the gene can no longer produce the ANGPTL3 protein. Without this protein inhibiting lipid clearance, cholesterol and triglyceride levels fall.
The effect is expected to be permanent because the genetic change occurs in the liver cells’ DNA itself. As those cells divide and are replaced over time, the edited DNA is replicated, maintaining the therapeutic effect.
This represents a fundamentally different approach than conventional medications, which must be taken continuously because they don’t change underlying biology. Gene editing changes the biology itself.
Safety Profile
A paramount question for any gene-editing therapy is safety. Permanently modifying DNA raises concerns about unintended effects.
In this trial, no serious adverse events were attributed to the treatment during the short-term monitoring period. Three patients experienced minor reactions—back pain and nausea—that resolved with standard medication. One patient developed temporarily elevated liver enzymes that normalized without intervention.
The study included careful monitoring for off-target editing—instances where CRISPR might cut DNA at unintended locations. No evidence of problematic off-target effects was detected.
However, fifteen patients followed for 60 days represents only the beginning of safety assessment. The researchers have planned monitoring extending to at least one year, with long-term safety follow-up continuing for fifteen years. Gene editing is permanent, so long-term surveillance is essential.
Context in Cardiovascular Medicine
This trial doesn’t exist in isolation. It represents the convergence of several advancing technologies and growing understanding of cardiovascular genetics.
CRISPR technology has matured dramatically since its discovery. The 2020 Nobel Prize in Chemistry recognized Jennifer Doudna and Emmanuelle Charpentier for developing this gene-editing system. Since then, researchers have steadily improved its precision, delivery methods, and clinical applicability.
Simultaneously, genetic research has identified numerous genes that influence cardiovascular risk. ANGPTL3 emerged as a particularly attractive target because rare individuals who naturally lack functional copies of this gene have exceptionally low cholesterol and triglyceride levels—and remarkably low rates of cardiovascular disease—without apparent health problems.
Lipid-lowering drug development has also advanced, with injectable medications like PCSK9 inhibitors already demonstrating that infrequent dosing can achieve substantial cholesterol reduction. But even these require injections every few weeks indefinitely. A true one-time treatment remained elusive until now.
Practical Considerations
If CTX310 progresses through clinical trials and eventually receives approval, several practical considerations will shape its use.
Cost is likely to be significant. Gene therapies typically carry high price tags, reflecting the complexity of their development and manufacturing. Whether a one-time cost ultimately proves more economical than lifetime medication depends on the specific prices and individual patient factors.
Patient selection will be important. The current trial enrolled patients with uncontrolled lipids despite existing therapy—a population with clear unmet need. Whether gene editing makes sense for patients who could manage their cholesterol with inexpensive generic statins is a different question.
Access and delivery present logistical challenges. The treatment requires intravenous infusion in a clinical setting, not a prescription picked up at a pharmacy. Healthcare systems would need to accommodate this different model of care.
And questions of reversibility arise. Unlike medications that can be stopped if problems emerge, gene editing is permanent. This raises the bar for safety evidence required before widespread adoption.
Looking Forward
The Phase 1 results represent proof of concept—demonstration that CRISPR gene editing can safely reduce cardiovascular risk factors with a single treatment. Larger trials will be needed to confirm efficacy across broader patient populations and to establish long-term safety.
Other companies are developing similar approaches targeting different lipid-regulating genes, creating competition that could accelerate progress and potentially reduce costs. The field is moving rapidly.
For patients struggling with high cholesterol despite existing treatments—and for the many more who simply find lifetime medication unsustainable—this research offers a glimpse of a different future. Not managing a chronic condition, but permanently correcting the biological tendency that creates it.
The path from fifteen patients to standard clinical practice remains long. But the destination—cardiovascular protection from a single treatment—has never seemed more achievable.
Sources
1. Laffin LJ, et al. “CRISPR-Cas9 Gene Editing of ANGPTL3 in Patients with Elevated Triglycerides.” New England Journal of Medicine. November 2025.
2. Cleveland Clinic Newsroom. “Cleveland Clinic First-In-Human Trial of CRISPR Gene-Editing Therapy Shown to Safely Lower Cholesterol and Triglycerides.” November 8, 2025. https://newsroom.clevelandclinic.org/2025/11/08/cleveland-clinic-first-in-human-trial-of-crispr-gene-editing-therapy-shown-to-safely-lower-cholesterol-and-triglycerides
3. American Heart Association Newsroom. “First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides.” November 2025. https://newsroom.heart.org/news/first-in-human-trial-of-crispr-gene-editing-therapy-safely-lowered-cholesterol-triglycerides
